Stryker reported quarterly results that fell short of Wall Street projections, citing muted demand in several complex procedural areas even as the company maintained its full-year adjusted profit outlook.
For the quarter ended March 31, the Michigan-based medical device manufacturer posted total revenue of $6.02 billion, below analysts' expectations of $6.35 billion compiled by LSEG. On an adjusted basis, Stryker recorded earnings of $2.60 per share, missing the consensus estimate of $2.98 per share.
Despite the quarterly shortfall, Stryker reiterated its guidance for adjusted full-year profit in a range of $14.90 to $15.10 per share.
Segment performance
Sales in Stryker's largest reporting unit, Medical Surgery and Neurotechnology, increased 5% to $3.21 billion for the quarter, but this figure came in under analysts' estimates of $3.83 billion. The Orthopedics segment produced a 6.3% sales increase to $2.81 billion, outperforming expectations of $2.51 billion.
The company manufactures joint replacements and implants used to repair broken bones and competes closely with major peers across hips, knees, trauma care and sports medicine.
Market reaction and operations
Stryker's shares fell 1.8% in extended trading following the release of results.
The company also reported operational disruptions tied to a cyber incident claimed in March by a group known as Handala. That attack reportedly limited access to some of Stryker's systems and caused delays to certain surgeries. Company staff and contractors posted on social media that the hacking group's logo appeared on login pages; those social posts could not be independently verified.
What the results mean
The quarter highlights a mixed commercial picture: one of Stryker's largest units missed revenue expectations while its orthopedics business exceeded forecasts. Management's decision to hold the full-year adjusted earnings range unchanged signals confidence in longer-term margins and cash generation assumptions, despite near-term demand softness and the operational challenges from the cyber incident.
Investors and industry observers will likely monitor subsequent quarters to see whether trends in complex procedure volumes stabilize and whether any lingering effects from the March cyber disruption persist.